Aberrant PD-L1 (CD274) expression has been described in different types of tumour and linked to tumour aggressiveness and a poor prognosis. In primary colorectal carcinomas (CRCs), CD274 expression was reported to be associated with mismatch repair (MMR)-deficiency, BRAF mutation, and "stem-like" immunophenotype defined by down-regulation of homeobox protein CDX2 and membranous expression of activated leukocyte cell adhesion molecule (ALCAM). However, the immunophenotype and genotype of CD274-positive metastatic CRC have not been extensively analysed. In this study, 189 CRC metastases were evaluated immunohistochemically for CD274, MMR proteins, CDX2, and ALCAM expression. Immunostaining for CD4, CD8, and FOXP3 was also performed to characterize tumour-associated immune cells. In addition, 34 arbitrarily selected lesions were genotyped using Sanger-and next-generation sequencing. Univariate analyses showed no clear association between CD274 expression and clinicopathological parameters including MMR-deficiency or "stem-like" immunophenotype after adjustment for multiple testing. Comparison of the clinicopathological profiles of CD274-positive primary and metastatic tumours revealed in the latter younger age of occurrence (60.9 6 13.3 versus 72.6 6 13.1 years, p 5 0.001), cytoplasm-dominant CD274 expression (p < 0.001), infrequent MMR-deficiency (p < 0.001), and common KRAS mutations (54%, p < 0.001). In five cultured colon cancer cell lines, CD274 was expressed and modulated after exogenous exposure to IFNc and TGF-b1. Thus, CD274 regulation mechanisms might include tumour micro environmental factors. Based on significantly different characteristics in CD274-positive metastatic and primary CRCs, evaluation of metastases should also be considered when planning immune checkpoint inhibitor therapy.
Introduction
The PD-Ls (programmed cell death ligands)/PDCD1 (programmed cell death 1, PD-1) axis is crucial for the modulation of the immune system to reduce peripheral tissue damage from excess inflammatory responses. The PD-Ls/PDCD1 axis has also been reported to play a pivotal role in the maintenance of self-tolerance to avoid autoimmune diseases [1, 2] .
CD274 (B7-H1, PD-L1) has been identified as a cell-surface glycoprotein belonging to the B7 family. Physiologically, CD274 is primarily induced by interferon-c (IFNc) from T helper 1 (TH1) cells under inflammatory conditions [3] [4] [5] [6] .
Variable CD274 expression has been reported in different types of tumour, including oesophageal, gastric, colorectal, and lung cancers. In some cases, CD274 expression was linked to tumour aggressiveness and a poor prognosis [7] [8] [9] [10] . In primary colorectal carcinomas (CRCs), CD274 expression was reported to be associated with mismatch repair (MMR)-deficiency, BRAF mutation, and "stem-like" immunophenotype defined by down-regulation of CDX2 (caudal-type homeobox transcription factor 2), an intestinal differentiation marker, and membranous expression of activated leukocyte cell adhesion molecule (ALCAM, CD166), a stem cell marker [11] [12] [13] [14] . However, those characteristics have not been fully evaluated in metastatic colorectal cancer.
In this study, a cohort of metastatic CRCs was evaluated immunohistochemically for CD274, MMRproteins, CDX2, and ALCAM expression. Immune phenotypes of tumour-infiltrating inflammatory cells were also assessed by CD4, CD8, and FOXP3 immunostaining. In addition, 34 arbitrarily selected metastases were screened for gain-of-function mutations in the BRAF, KRAS, NRAS, and PIK3CA oncogenes. Phenotypic and genotypic characteristics of the two CD274-positive cohorts consisting of metastatic CRCs evaluated in this study and previously reported primary tumours [13] were compared. Furthermore, to evaluate the regulation mechanism(s) of CD274 in colon cancer cells, CD274 expression, and responsiveness to exogenous INFc and TGF-b1 were examined.
This study attempts to identify the clinicopathological profile of metastatic CRCs potentially targetable by immune checkpoint inhibitors against the CD274/ PDCD1 axis.
Materials and methods

Tissue samples
A total of 189 anonymized metastatic CRCs were collected. This project was completed under Office of Human Subject Research Exemption with anonymized specimens. Tumours were assembled into multitumour blocks containing approximately 50 rectangular tissue samples as previously described [15] . The size of tumour tissue samples was estimated to exceed the size of a single 0.6 mm 2 core by a factor of 10-15. All cases were extensively characterized. Tumour differentiation, mucus production, solid/sheet-like proliferation, and existence of tumour-associated immune cells (TAIs), at least 50 TAIs/high-power field (HPF) within or adjacent tumour foci, were evaluated in haematoxylin and eosin (H&E) stained sections.
Immunohistochemistry
The antibodies used for immunohistochemistry are summarized in supplementary material, Table S1 , available online. All immunostaining was performed with Leica Bond-Max automation and the Leica Refine detection kit (Leica Biosystems, Bannockburn, IL, USA) as previously reported [10, 13, 16] . Immunoreactivity of CD274 (membrane and/or cytoplasm) and ALCAM (membrane) was evaluated with a detection cut-off of 5% according to our previous reports [10, 13] . Representative photographs for CD274-positive metastatic CRC cases are shown in Figure 1 . CDX2 immune reactivity (nucleus) was classified into two categories; positive (same or stronger than the normal colonic mucosa) and down-regulated (weaker than the normal colonic mucosa or loss of expression). "Stem-like" immunophenotype was defined by CDX2-down-regulation and ALCAM-positivity (representative photographs in supplementary material, Figure S1 ). Immunohistochemistry for MMR proteins (MLH1, MSH2, MSH6, and PMS2) was performed as previously reported [10, 13] . A threshold of 50 positive TAIs/HPF was used to define CD4, CD8, and FOXP3-positive cases.
Genotyping
Sanger sequencing for BRAF, KRAS, and NRAS was performed on 34 arbitrarily selected metastatic lesions and cell lines as previously reported [13, 16] . Primer sequences, PCR conditions and size of amplicons, are provided in supplementary material, Table S2 . Nine metastases, carrying wild-type BRAF, KRAS, and NRAS genes, were subsequently evaluated by next-generation sequencing (NGS) using the Ion AmpliSeq TM Cancer Hotspot Panel v2 Kit (targeting 50 known oncogenes and tumour suppressor genes) and Ion Torrent TM platform following the manufacturer's instructions (Life Technologies/Thermo Fisher Scientific, Waltham, MA, USA) and previously published procedure [17] . All experiments were carried out in a blinded manner.
Statistical analysis
Histopathological, immunohistochemical, and genetic data for primary CRCs were derived from our previous study [13] . Chi-square or Fisher's exact test was performed with EZR version 1.32 software [18] to analyse the statistical correlation between categorical data. Simple Bonferroni correction for multiple hypothesis testing was applied to generate an adjusted two-sided alpha level. Cases with missing information were eliminated from the statistical analysis of that parameter.
Cell culture, reverse transcription quantitative polymerase chain reaction (RT-qPCR), immunoblot assay, and Fluorescence-activated cell sorting (FACS) analysis from American Type Culture Collection (ATCC, Manassas, VA, USA). BRAF and KRAS mutations were previously reported in these cell lines; BRAF p.V600E in COLO205, KRAS p.G13D in HCT116, KRAS p.G12V in SW480, and KRAS p.G13D and A14V in LoVo [19, 20] . Identical BRAF and KRAS mutations were identified in the cell line cultures used in this study (data not shown).
Cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) with a supplement of 10% fetal bovine serum. IFNc or TGF-b1 (R&D systems/ Thermo Fisher Scientific, Waltham, MA, USA) were added to the culture medium at the indicated concentration and duration. JAK inhibitor I (Calbiochem/ Merck Millipore, Darmstadt, Germany) blockade was performed an hour prior to IFNc addition. Total RNAs and whole-cell lysates were prepared and subjected to RT-qPCR and immunoblot analyses using a previously reported procedure [19] [20] [21] . Details of the antibodies for immunoblot assays are summarized in supplementary material, Table S3 . Signal intensity was measured using ImageJ software (NIH, Bethesda, MD, USA).
In FACS analyses, PE-conjugated anti-CD274 antibody (BioLegend, Inc., San Diego, CA, USA) was applied to harvested colon cancer cells at a dilution of 1:20 for an hour on ice. After washing and staining with 7-AAD (Beckman Coulter, Inc., Brea, CA, USA), the cells were analysed using a FACSCanto II flow cytometer (BD Biosciences, Franklin Lakes, NJ, USA). Collected data were analysed by FlowJo 7.6.5 software (Tomy Digital Biology Co., Ltd., Taito-ku, Japan).
Results
Clinicopathological and immunohistochemical characteristics of metastatic CRCs
One hundred eighty-nine metastatic CRCs including 110 (58%) liver metastases were evaluated in this study. Clinical data are summarized in Table 1, while  Table 2 presents pathological and immunohistochemical characteristics according to CD274 expression. CD274-positive metastatic CRCs had a tendency to Comparison between CD274-positive primary and metastatic CRCs Table 3 outlines the clinicopathological characteristics of 26 CD274-positive metastatic CRCs and previously reported 54 CD274-positive primary colorectal tumours [13] . The patient cohorts for metastatic and primary tumours were different. The mean age of the patients with metastatic lesions (60.9 6 13.3 years) was significantly lower than those with primary lesions (72.6 6 13.1 years, p 5 0.001). Metastatic tumours showed dominant cytoplasmic CD274 expression (88% versus 44%, p < 0.001). Most CD274-positive primary tumours (74%, [40/54]) carried a MMR-deficient phenotype, while MMR-deficiency was rarely detected (12%, [3/26] , p < 0.001) in metastatic CD274-positive lesions. Also, CRC metastases displayed solid/sheetlike proliferation (8% versus 37%), CDX2-downregulation (27% versus 54%), and "stem-like" immune phenotype (8% versus 31%) less frequently than primary colorectal tumours. Although no significant difference was detected, ALCAM positivity was lower in metastatic CRCs (31% versus 48%).
Mutation analyses of metastatic CRCs
Thirty-four arbitrarily selected metastatic lesions including 13 CD274-positive tumours were evaluated for BRAF, KRAS, and NRAS mutations using Sanger sequencing. The results are summarized in supplementary material, Table S4 . In seven CD274-positive metastases, KRAS mutations, p.G12V (n 5 3), p.G12D (n 5 2), p.G12C (n 5 1), and p.G13D (n 5 1) were identified. Three CD274-expressing metastases were BRAF p.V600E mutants. Subsequently, nine BRAFand RAS-wild-type metastases were evaluated by NGS. In two cases, PIK3CA p.H1047R mutation was detected whereas seven KRAS, NRAS, BRAF, and PIK3CA (quadruple negative) wild-type lesions carried mutations affecting TP53 (n 5 3), CDKN2A (n 5 2),
, and STK11 (n 5 1). The 13 CD274-positive colorectal metastases included KRAS (n 5 7), BRAF (n 5 3), and PIK3CA (n 5 1) mutants, and two quadruple negative tumours. One of the latter carried TP53 mutation.
Genotype comparison of primary and metastatic CD274-positive CRCs
The gene mutation status of 13 CD274-positive metastatic lesion evaluated in this study and 16 previously studied CD274-positive primary CRCs [13] are summarized in Table 4 . Most CD274-expressing primary tumours (88%, [14/16] ) were BRAF mutants. In contrast, CD274-expressing metastatic CRCs frequently carried KRAS mutation (54%, [7/13] ). The significance of this difference was confirmed statistically (p < 0.001). Detailed clinicopathological, immunohistochemical, and gene mutation data from the CRCs analysed are summarized in supplementary material, Tables S4 and S5 .
Characterization of five colon cancer cell lines
Immunoblot assay revealed variable CD274 expression in all analysed colon cancer cell lines (Figure 2A) . A significant fraction (3.2-32.0%) of colon cancer cells expressed CD274 on the cell membrane under culture conditions ( Figure 2B ). High-level phospho-STAT1 (Tyr701) expression indicating aberrant JAK-STAT pathway activation was detected in CW-2. CDX2 was silenced in COLO205 and HCT116. VIM expression suggesting a mesenchymal-like phenotype was shown in SW480 and LoVo with lower CD274 expression levels ( Figure 2C and supplementary material, Figure S2 ). Among the five analysed cell lines, COLO205 and SW480 appeared to be derived from microsatellite-stable tumours based on the MMR protein expression status ( Figure 2C ). COLO205 was considered a consensus molecular subtype 1 (CMS1) tumour because of its BRAF mutation, CDX2-negativity, and epithelial phenotype (Figure 2C and supplementary material, Figure S2 ) [22] .
IFNc up-regulates CD274 through the JAK-STAT pathway
Twenty-four hours of IFNc stimulation up-regulated membranous CD274 expression on all of the colon cancer cells in a dose-dependent manner ( Figure  3A ,B). Pre-treatment with JAK inhibitor I blocked CD274-and phospho-STAT1/3 up-regulation induced by IFNc ( Figure 3C ). Thirty-six hours of JAK inhibitor I blockade slightly suppressed CD274 expression with down-regulated phospho-STAT1 in CW-2 ( Figure 3D ).
TGF-b1 modulates CD274 regardless of EMT (epithelial-mesenchymal transition) status
Forty-eight hours of TGF-b1 stimulation mildly upregulated cell surface CD274 in HCT116. On the other hand, CD274 was down-regulated in Lovo and CW-2 by TGF-b1 ( Figure 4A,B) . SW480 uniquely showed a mild EMT phenotype (CDH1 downregulation with VIM up-regulation) upon TGF-b1 stimulation ( Figure 4B ). However, no clear correlation between EMT phenotype including VIM upregulation and CD274 down-regulation was seen under our experimental conditions ( Figure 4B ).
Discussion
In this study, 189 well characterized metastatic CRCs were examined immunohistochemically for CD274 (PD-L1), MMR-protein, CDX2, and ALCAM expression in order to assess the characteristics of CD274 CRCs, colorectal carcinomas; *P value was calculated using Fisher's exact test.
Characterization of CD274-positive metastatic colorectal carcinoma 273
V immunostaining. In addition, Sanger sequencing and NGS were performed in a representative subgroup of metastases. These characteristics of metastatic CRCs were compared to those of primary tumours from our previous study [13] . However, a limitation in the comparison is that the patient cohorts are different. Finally, CD274 expression and responsiveness to exogenous INFc or TGF-b1 were examined in cultured colon cancer cells to assess the regulation mechanism(s) of CD274 expression. Approximately 15% of primary colorectal cancers, recently classified as consensus molecular subtype 1 (CMS1), are believed to develop through the serrated neoplasia pathway, showing mucinous and/or poorly differentiated/medullary histology, CpG island methylator phenotype, MMR-deficiency, mutational BRAF activation and, in some cases, CDX2-negativity [14, 22, 23] . In primary colorectal tumours, significant associations between CD274 expression and characteristics of serrated neoplasia pathwaydriven CRCs have been identified [11] [12] [13] . In CMS1 colorectal cancers, similar to other tumour-driving intrinsic factor/signalling pathway(s) such as PTENloss, EGFR-mutation, or ALK-translocation [24] [25] [26] , activated serrated neoplasia or JAK-STAT pathways, have been suggested to be associated with high CD274 expression [22] .
In metastatic CRCs, 14% of the cases analysed showed variable CD274 expression. In contrast with primary CRCs, univariate analyses failed to identify significant association between CD274 expression and tumour intrinsic factors including MMRdeficiency (p 5 0.42), ALCAM expression (p 5 0.23), and "stem-like" immunophenotype (p 5 0.63) after multiple testing adjustments [13] . The comparison of CD274-positive metastatic and primary CRCs revealed earlier occurrence (p 5 0.001), and decreased membranous CD274 expression (p < 0.001) and MMRdeficiency (p < 0.001) in metastatic tumours. Also, different mutation status (common KRAS mutation in CD274-positive metastatic tumours) was identified (p < 0.001). Because concordant gene mutation status and phenotype have been previously reported between primary and metastatic colorectal lesions [27] , the higher incidence of KRAS mutants and lower frequency of MMR-deficiency might point to different mechanisms triggering CD274 expression in metastatic and primary CRCs. Also, intra-tumour heterogeneity or differential expression of CD274 in isogenic primary and metastatic tumours has been reported in several types of cancer such as lung cancer, breast carcinoma, and renal cell carcinoma [28] [29] [30] . The lines of evidence presented here strongly support previous observations that tumour micro environmental factor(s) rather than tumour-intrinsic factors dominantly regulate CD274 expression [31] . In the current study, CD274 up-regulation mechanisms were studied "in vitro" using five colon cancer cell lines. All cultured colon cancer cells (5/5) expressed CD274 at variable levels with no significant correlation with BRAF/KRAS mutations, MMRdeficiency, CDX2, or phospho-STAT1 expression levels. In CMS1 colorectal tumours, aberrantly activated JAK-STAT pathway was suggested [22] . However, phospho-STATs were not expressed at a detectable level in COLO205 cells under cultured conditions. Therefore, the activated JAK-STAT pathway phenotype in CMS1 tumours might originate from the association with TAIs because prominent infiltration of T and NK cells was identified in this type of tumour [22] . Conversely, CW-2 showed aberrant expression of phospho-STAT1 with an unclear mechanism. JAK inhibitor I uniquely suppressed CD274 expression in CW-2 suggesting that aberrant JAK-STAT pathway activation plays some role in CD274 up-regulation. In the present study, all of the cell lines, regardless of their subtype, were responsive to exogenous INFc for CD274 up-regulation through the JAK-STAT pathway. Although histological and immunohistochemical analyses showed no significant association between CD274 expression and TAIs, these experimental results suggest that INFc from inflammatory cells within the tumour micro environment could modulate CD274 expression.
Inverse correlation between CD274-and VIMexpression (one of the EMT phenotypes) was suggested in immunoblot analyses of colon cancer cells. Based on these observations, colon cancer cells were tested using TGF-b1 stimulation, one of the notable EMT-inducers, for CD274 down-regulation. Contrary to our expectations, TGF-b1 variably regulated CD274 expression in colon cancer cells regardless of the EMT phenotype. TGF-b signalling in colon cancer cells is complicated. At first, it was reported that EMT can only be induced by TGF-b1 in microsatellitestable colon cancer cells with wild-type TGFBR2 through its normal canonical TGF-b1-SMAD2 signalling [32] . However, a recent study showed that signals can be transduced through the canonical TGF-b1-SMAD2 pathway even in microsatellite-unstable colon cancer cells with TGFBR2 frameshift mutation through the production of functional TGFBR2 protein by transcriptional slippage [33] . Actually, HCT116 showed SMAD2 phosphorylation upon TGF-b1 stimulation in the present study (supplementary material, Figure S3 ). Conversely, microsatellite-stable COLO205 did not show EMT even with activation of the canonical TGF-b1-SMAD2 signalling (supplementary material, Figure S3 ). In the present study, bidirectional CD274 regulation by exogenous TGF-b1 stimulation was identified. These results might indicate the involvement of not only canonical TGF-b1-SMAD2 signalling but also the SMAD2-independent non-canonical TGF-b1 pathway and/or epigenetic mechanism due to the CpG island methylator phenotype for the regulation of EMT and CD274 expression in colon cancer cells [34] . These complicated mechanism(s) should be examined further.
PD-Ls/PDCD1 immune checkpoint inhibitors have been introduced as cancer treatment and have shown significant anti-cancer effects in some cases [35, 36] . At the time of submission of this manuscript, several clinical trials (such as NCT02060188 and NCT02437071) were in progress to assess CD274/ PDCD1 immune checkpoint inhibitors in metastatic colorectal cancer patients. CD274 immunohistochemistry has been used as a potential biomarker to predict clinical response to PD-Ls/PDCD1 immune checkpoint inhibitors as well as resistance to aspirin therapy [35] [36] [37] [38] [39] . In the present study, a significant number of metastatic CRCs (88%, [23/26] ) showed cytoplasmdominant CD274 expression. Future retrospective studies should address whether decreased membranous CD274 on metastatic CRC cells dampens the efficacy of PD-Ls/PDCD1 immune checkpoint inhibitors. The discordance of CD274 expression between primary and metastatic lesions can result in non-optimal use of CD274/PDCD1 axis inhibitors. Thus, CD274 immunohistochemistry of both primary and metastatic CRCs should be examined when planning anti-PD-Ls/ PDCD1 immune checkpoint inhibitor treatment for colorectal cancer patients.
In summary, this study has identified immunohistological and genotypic characteristics of CD274-positive metastatic CRCs, showing significant differences between CD274 positive primary and metastatic lesions and indicating epigenetic mechanisms, such as tumour micro environmental factors, in regulation of CD274 expression.
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